TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Does Dose Adjustment of Nicotine Replacement Therapies According to Saliva Cotinine Increase Efficacy of These Treatments of Assistance To the Nicotinic Weaning Of the High-Risk Patients?
Brief Summary: Nicotine replacement therapies (NRT) have proven efficacy to help smokers quit. However, their effectiveness is low. This study aims to answer the question: Does the dose adjustment of NRT according the saliva concentration of nicotine's main metabolite: cotinine improve their efficacy compared with the lack of dose adjustment (usual care) in smoking patients with smoking related disease condition.


Options:
A: Inclusion Criteria:

- Active smokers over 40 years and more than 10 pack-years

Exclusion Criteria:

* Previous diagnosis of respiratory disease (asthma, COPD, interstitial lung disease) that cause alteration of spirometric pattern.
* Patients with limitations in performing spirometry
* Age greater than 80 years
* Institutionalized patients
* Patients with a life expectancy less than 1 year
* Spirometry in the past 2 years
B: Inclusion Criteria:

* All patients 40 years or older
* Seen at least once in the past 2 years (active patients) by their PCP
* And/or 40 years of age and less than 81 years of age who smoke.

Exclusion Criteria:

* \< 40 years of age
C: Inclusion Criteria:

* Age ≥18 years Smoking ≥ 10 cigarettes per day Patients with disease conditions known to be related to smoking: e.g.coronary heart diseases, COPD, lower extremity arterial disease, etc

Exclusion Criteria:

* Smokers whose follow-up during the duration of the study, in a predictable way, cannot be assured.
* smokers having been treated by bupropion ( Zyban) during two months preceding the inclusion
* persons under TSN, neuroleptic, substitute treatments in OPINOIDES, under anticoagulants-non-equilibrating,
* encircled woman
* breast-feeding woman
* Contraindication usual of the TSN
D: Inclusion Criteria:

* Smoker of at least 10 cigarettes per day on average over the past 12 months
* Inpatient with an anticipation admission of at least one day
* Willingness to quit smoking
* Aged between 20 and 75 years
* A plan of discharge to go home
* Acute hospital admission with cardiovascular, cerebrovascular, peripheral vascular diseases or airways (asthma and/or Chronic Obstructive Pulmonary disease

Exclusion Criteria:

* Subject preference to use an alternative pharmacotherapy for smoking cessation
* Respiratory patient being considered for home oxygen
* Pregnancy
* Breast feeding
* Acute or pre-existing severe psychiatric illnesses
* Past history of psychosis or suicidal ideation
* Renal impairment with creatinine clearance \<30ml/min

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)
Brief Summary: This is a four-year study, funded by the Center for Disease Control and Prevention, related to antimicrobial resistance in rural communities. The project consists of four components: A) surveillance of antimicrobial resistance, B) promotion of appropriate antimicrobial drug prescribing, C) preliminary assessment of the environmental impact of antimicrobials, and D) the development of new antimicrobial products. Six rural communities in Utah, and six rural communities in Idaho are participating in this study. Component D is being performed by investigators at Harvard University, under the direction of Co-Investigator Roger Inouye.


Options:
A: Inclusion Criteria:

* Suspected upper respiratory infection patients in 12 rural communities in Utah and Idaho

Exclusion Criteria:

-
B: FAMILY PHYSICIANS:

Inclusion Criteria:

* All FP (teachers and residents) providing care in the walk-in clinic in each Family Practice Teaching Unit (FPTU) will be eligible to participate in the trial.

Exclusion Criteria:

* he/she was involved or participated in the DECISION + pilot RCT
* he/she is not expected to be practicing at the FPTU for the whole duration of the study (e.g. residents ending their residency program or doing rotations outside of the FPTU, planned pregnancy/delivery, planned retirement).

PATIENTS:

Inclusion Criteria:

* if 17 years old and under, must be accompanied by a parents or a guardians)
* they are consulting a participating physician for an ARI, for which treatment with an antibiotic is considered
* they are able (patients or the accompanying parent or guardians) to read, understand and write French (expected level: 8th grade)
* they give informed consent

Exclusion Criteria:

* Patients with a condition requiring emergency care will be excluded.
C: Inclusion Criteria:

* Partners-affiliated pediatric practice providers utilizing Longitudinal Medical Record (LMR), which is an electronic health record system. Also the parents of the patients of the above noted pediatric providers.

Exclusion Criteria:

* Non-Partners providers, or Partners providers who do not use LMR. Parents of patients not seen by Partners-affiliated pediatric providers who use LMR.
D: Inclusion Criteria:

* Primary care practice sites within the Geisinger Health System

Exclusion Criteria:

* Sites with \< 1000 visits per year for acute respiratory infection

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of Symbicort Single Inhaler Therapy on Bronchial Hyper Responsiveness, Asthma Control and Safety in Mild to Moderate Asthmatics in General Practice, Compared to Usual Care Therapy
Brief Summary: The primary objective is to compare the effects of Symbicort SiT and treatment according to NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by PD20 histamine, and to validate the Bronchial Hyperresponsiveness Questionnaire (BHQ).


Options:
A: Inclusion Criteria:

* Diagnosed with asthma since at least 6 months prior to first visit
* Prescribed daily use of glucocorticosteroids for at least 3 months prior to first visit
* At least one asthma exacerbation more than one but less than twelve months prior to first visit

Exclusion Criteria:

* Respiratory infection affecting asthma within 30 days before first visit
* Use of oral, rectal, or parenteral glucocorticosteroids for within 30 days before first visit
* Any significant disease or disorder that may jeopardize the safety of the patient

Additional inclusion and exclusion criteria will be evaluated by the Investigator.
B: Inclusion Criteria:

* Diagnosis of asthma \< 3 months
* Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1

Exclusion Criteria:

* Smoking history \> 10 pack-years
* Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion
* Any significant disease or disorder that my jeopardize the safety of the patient.

Additional inclusion and exclusion criteria will be evaluated by the investigator.
C: Inclusion Criteria:

* Patients at out-patient clinics
* \>18 years with a minimum of 6 months documented history of persistent asthma who have used inhaled glucocorticosteroids for at least one month and have a history of use in rapid-acting B2 agonists for symptom relief

Exclusion Criteria:

* Asthma exacerbation within the last 14 days prior to study start
* subject aged \>40 years with a smoking history of \>10pack-years
* subjects with chronic obstructive lung disease or other significant respiratory disease
D: Inclusion Criteria:

* diagnosis of mild to moderate asthma, FEV1 ³ 60% of predicted normal values pre-bronchodilator, daily use of inhaled GCS during the last 3 months

Exclusion Criteria:

* Regular need of \>4 inhalations of a short-acting b2-agonist/day, known or suspected hypersensitivity to any of the investigational drugs or inhaled lactose, use of any b-blocking agent, having smoked ³10 pack-years

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder
Brief Summary: The purpose of this study is to assess the effectiveness and safety of long-acting risperidone given as a once monthly injection to adult patients with schizophrenia or schizoaffective disorder.


Options:
A: Inclusion Criteria:

* Diagnosis of schizophrenia or schizoaffective disorder
* stable with respect to disease symptoms and other medical conditions
* stable on antipsychotic therapy with oral risperidone 2 to 6 milligrams per day for 8 weeks before study
* if female, using birth control.

Exclusion Criteria:

* Hospitalized within 8 weeks of beginning the study
* at risk to self or others
* presence of liver or kidney damage
* use of oral antipsychotic drugs other than risperidone within the past 8 weeks, of injected antipsychotics within the past 6 months, of long-acting risperidone in an earlier study, of investigational drugs within the past 30 days, or of electroconvulsive therapy within the past 12 months
* pregnant or breast-feeding
* if female, not using birth control
* abusing drugs or alcohol.
B: Inclusion Criteria:

* After the acute treatment of the first-episode in schizophrenia (according ICD-10 F20)
* Age between 18 and 55
* Informed consent

Exclusion Criteria:

* Residence outside of the catchment area
* Legal reasons
* Insufficient knowledge of the German language
* Substance abuse or addiction
* Pregnancy
* Serious physical illness
* Organic brain disease
* Contraindication to neuroleptic treatment
C: Inclusion Criteria:

* first-episode schizophrenia

Exclusion Criteria:

* acute psychosis
D: Inclusion Criteria:

* Patients after 1 year of maintenance treatment after their first-episode in schizophrenia (according ICD-10 F20)
* Age between 18 and 55
* Informed consent
* One year neuroleptic maintenance treatment
* Reaching stable course

Exclusion Criteria:

* Residence outside of the catchment area
* Legal reasons
* Insufficient knowledge of the german language
* Substance abuse or addiction
* Pregnancy
* Serious physical illness
* Organic brain disease
* Contraindication to neuroleptic treatment

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Brief Alcohol Intervention for Incarcerated Women
Brief Summary: The purpose of this study is to examine the efficacy of a brief motivational intervention for alcohol use in incarcerated women.


Options:
A: Inclusion Criteria:

* 18 years of age or older
* Fluent in English or Spanish
* Consume risky amounts of alcohol
* Provide 2 contacts to assist with follow-up
* Have no plans to move from the local area within a year of screening
* Score \>21 on Mini-Mental State Examination (no serious cognitive impairment)
B: Inclusion Criteria:

* All patients aged 18 or older attending to the emergency department were potentially eligible patients
* Patients with an AUDIT-C score higher than 6 points for men and 5 for woman were invited to participate

Exclusion Criteria:

* Cognitive impairment
* Medically unstable
* Patients explicitly demanding alcohol treatment
C: Inclusion Criteria:

* incarcerated women
* current hazardous drinking
* current HIV risk behavior

Exclusion Criteria:

-
D: Inclusion Criteria:

* Male and female inpatients 18 years of age or older.
* Participants will have a current DSM-IV diagnosis of alcohol abuse or dependence.
* Able to understand/speak English
* Participants will have signed a witnessed informed consent.

Exclusion Criteria:

* Cognitive impairment (e.g., mental retardation)
* Participants who meet current DSM-IV criteria for bipolar disorder, schizophrenia, or dementia
* Participants who are homeless, without contact person
* Participants enrolled in a methadone maintenance treatment program.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Brief Alcohol Intervention for Incarcerated Women
Brief Summary: The purpose of this study is to examine the efficacy of a brief motivational intervention for alcohol use in incarcerated women.


Options:
A: Inclusion Criteria:

* 18 years of age or older
* Fluent in English or Spanish
* Consume risky amounts of alcohol
* Provide 2 contacts to assist with follow-up
* Have no plans to move from the local area within a year of screening
* Score \>21 on Mini-Mental State Examination (no serious cognitive impairment)
B: Inclusion Criteria:

* adolescents (ages 14-18) presenting to the ED for a medical injury or illness (except exclusions as noted below)
* adolescents ability to provide informed assent/consent depending on age
* access to a parent or guardian to provide informed consent

Exclusion Criteria:

* adolescents who do not understand English
* prisoners
* adolescents classified by medical staff as "Level 1" trauma
* adolescents deemed unable to provide informed consent
* adolescents treated in the ED for suicide attempts
* adolescents triaged to the psychiatric ED
C: Inclusion Criteria:

* incarcerated women
* current hazardous drinking
* current HIV risk behavior

Exclusion Criteria:

-
D: Inclusion Criteria:

* Prescription drug abuse
* Prescription drug dependence
* Regular prescription drug consumption (\>60 times/last three months)

Exclusion Criteria:

* Current treatment for substance abuse problems
* Terminal illness

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The ADDITION Study. Anglo-Danish-Dutch Study of Intensive Treatment In PeOple With screeN Detected Diabetes in Primary Care
Brief Summary: The ADDITION study comprise 2 parts: screening for Type 2 diabetes and intensive treatment compared to standard treatment.

1. In the screening study, the feasibility and results of country specific models to identify undiagnosed individuals with Type 2 diabetes will be evaluated.
2. In the treatment study the effects of routine care in general practice according to local and national guidelines will be compared with an intensive ADDITION protocol, including structured lifestyle education (dietary modification, increased physical activity and smoking cessation) and intensive treatment of blood glucose, blood pressure and lipids, and prophylactic aspirin with or without motivational interviewing, on mortality, macrovascular and microvascular disease. Furthermore the impact of treatment on health status, treatment satisfaction and health service costs will also be assessed.


Options:
A: Inclusion Criteria:

Patients who will be included into the study will be from the following groups:

* White European subjects aged between 40-75 years
* Asian, Black, or Chinese subjects aged between 25-75 years

Exclusion Criteria:

Patients will be excluded from the study if they:

* Are housebound
* Have a terminal illness
* Have diabetes mellitus
* Have an active psychotic illness which deems them unable to give informed consent.
* Are pregnant or lactating
* Are taking part in any other clinical trials
B: Inclusion Criteria:

* 18+
* High risk of developing type 2 diabetes as identified through a risk score

Exclusion Criteria:

* Diagnosed diabetes
* Taking steroid medication
* Serious chronic illness preventing participation in trial
* Unable to speak English
C: Patients that will be included into the study if they have either / or

* Diagnosed with Pre-Diabetes (IGT or IFG)
* Aged 40 - 75 if English speaking European or 25 - 75 if South Asian
* Able to attend group education sessions

Exclusion Criteria:

Patients will be excluded from the study if they are:

* Unable to give consent
* Unable to attend group education sessions
* Diagnosis of diabetes at screening or during the study
* Require an interpreter for language other than South Asian
D: Inclusion Criteria:

Screening study: Every one aged 40-69 years (UK and DK) or 50-69 years(NL). Treatment study: All with screen detected type 2 diabetes.

Exclusion Criteria:

Participants are excluded if they already have diabetes at time of screening, are pregnant or lactating or have a severe psychotic illness, are house bound or have an illness with a likely survival of less than one year.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The ADDITION Study. Anglo-Danish-Dutch Study of Intensive Treatment In PeOple With screeN Detected Diabetes in Primary Care
Brief Summary: The ADDITION study comprise 2 parts: screening for Type 2 diabetes and intensive treatment compared to standard treatment.

1. In the screening study, the feasibility and results of country specific models to identify undiagnosed individuals with Type 2 diabetes will be evaluated.
2. In the treatment study the effects of routine care in general practice according to local and national guidelines will be compared with an intensive ADDITION protocol, including structured lifestyle education (dietary modification, increased physical activity and smoking cessation) and intensive treatment of blood glucose, blood pressure and lipids, and prophylactic aspirin with or without motivational interviewing, on mortality, macrovascular and microvascular disease. Furthermore the impact of treatment on health status, treatment satisfaction and health service costs will also be assessed.


Options:
A: Inclusion Criteria:

* Physician diagnosis of DM for more than 6 months;
* Glycated hemoglobin more than or equal to 8% within 3 months;
* Age:18-65 years.

Exclusion Criteria:

* Insulin pump users;
* Pregnant;
* Active substance, alcohol, or drug abuser;
* Psychotic or schizophrenic under active care;
* Severe hearing or visual impairment and other complications;
* Drug users (such as glucocorticoid or thyroid hormone) 3 months before the enrollment;
* No smartphone access.
B: Inclusion Criteria:

* Age 55 years or greater
* Being a current Medicare beneficiary (verified by the Centers for Medicare and Medicaid Services)
* Having diabetes mellitus as defined by a physician's diagnosis and being on treatment with diet, an oral hypoglycemic agent, or insulin
* Residence in a federally designated medically underserved area (either of two federal designations, Medically Underserved Area \[MUA\] or Health Manpower Shortage Area \[HPSA\]) in New York Sate
* Fluency in either English or Spanish

Exclusion Criteria:

* Moderate or severe cognitive, visual, or physical impairment
* The presence of severe co-morbid disease.
C: Inclusion Criteria:

* Adult patients \>= 25 years of age
* Type 2 diabetes for \>= 1 year
* Hemoglobin A1c \>= 7.5% and \<=11%
* Diabetes managed by exercise and diet, prescription oral medication or an injectable incretin mimetic

Exclusion Criteria:

* Type 1 diabetes
* On any type of insulin therapy at start of study
D: Inclusion Criteria:

Screening study: Every one aged 40-69 years (UK and DK) or 50-69 years(NL). Treatment study: All with screen detected type 2 diabetes.

Exclusion Criteria:

Participants are excluded if they already have diabetes at time of screening, are pregnant or lactating or have a severe psychotic illness, are house bound or have an illness with a likely survival of less than one year.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The ADDITION Study. Anglo-Danish-Dutch Study of Intensive Treatment In PeOple With screeN Detected Diabetes in Primary Care
Brief Summary: The ADDITION study comprise 2 parts: screening for Type 2 diabetes and intensive treatment compared to standard treatment.

1. In the screening study, the feasibility and results of country specific models to identify undiagnosed individuals with Type 2 diabetes will be evaluated.
2. In the treatment study the effects of routine care in general practice according to local and national guidelines will be compared with an intensive ADDITION protocol, including structured lifestyle education (dietary modification, increased physical activity and smoking cessation) and intensive treatment of blood glucose, blood pressure and lipids, and prophylactic aspirin with or without motivational interviewing, on mortality, macrovascular and microvascular disease. Furthermore the impact of treatment on health status, treatment satisfaction and health service costs will also be assessed.


Options:
A: Inclusion Criteria:Potential participants must be either parents, children or brothers and sisters of the affected person (individual with documented history of CHD).

More than 18 years of age.

-

Exclusion Criteria:

Bedridden and terminally ill patients. Those who are not willing to provide written informed consent will be also excluded.
B: Inclusion Criteria:

* Males and females aged 40 - 64 years living in sampled low income clusters in Durham region who are English speakers (including illiterate persons). Only one participant per residential household may participate.

Exclusion Criteria:

* Unable to provide informed consent
C: Inclusion Criteria:

Screening study: Every one aged 40-69 years (UK and DK) or 50-69 years(NL). Treatment study: All with screen detected type 2 diabetes.

Exclusion Criteria:

Participants are excluded if they already have diabetes at time of screening, are pregnant or lactating or have a severe psychotic illness, are house bound or have an illness with a likely survival of less than one year.
D: Inclusion Criteria:

* men aged 65-74 years old living in the central region of Denmark

Exclusion Criteria:

* men not aged 65-74 years
* men aged 65-74 years old not living in the central region of Denmark

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to determine the effects of cinnamon on serum glucose and lipid levels in people with non-insulin dependent type 2 diabetes mellitus.


Options:
A: Inclusion Criteria:

* Type 2 diabetics greater tahn 18 years of age

Exclusion Criteria:

* allergy to cinnamon pregnancy
B: Inclusion Criteria:

* Type 1 diabetes
* Treated with insulin for at least 12 months
* Either plan to become pregnant in the immediate future, willing to undertake pre pregnancy counselling, and has a screening HbA1c lesser than or equal to 12.0%, or
* Pregnant with normal singleton pregnancy, gestational age for at least 10 weeks at the time of randomisation, confirmed by ultrasound scan.

Exclusion Criteria:

* Previous birth of child with a major congenital malformation
* More than 2 previous multiple miscarriages or stillbirths
* Severe hyperemesis gravidarum, requiring hospitalisation, according to Investigator judgement
* Subjects being treated for infertility
* Proliferative retinopathy or maculopathy requiring acute treatment
* Drug or alcohol abuse
* Impaired renal, hepatic or cardiac function
C: Inclusion Criteria:

1. Patients with clinical Diagnosis of Type 2 diabetes requiring only behavioral or lifestyle intervention.
2. Fasting blood glucose in the range of 110-180 mg/dl
3. Age range - 35 to 60 years
4. Willing to participate in the study and perform all measurements

Exclusion Criteria:

1. Presence of any chronic disease or organ failure
2. Concurrent use of medication to control blood glucose levels
D: Inclusion Criteria:

* Type 2 diabetes mellitus
* HbA1C \> 6.0%
* Age 18 and above
* Able to obtain consent

Exclusion Criteria:

* Currently taking insulin
* Pregnancy
* End-stage renal disease
* Hemolytic anemia
* Cinnamon intolerance
* Inability or unwillingness to adhere to study protocol

Answer: D